At the biological level, cancer therapy can enhance survival at a specific end-point by two distinct mechanisms: an increase in cured fraction, and a lengthening of survival times among uncured patients (Boag, 1949; Gamel et al.,1990; Mould & Boag, 1975 (Freedman, 1982 level of P = 0.05. To increase the power of this trial from 80 to 90%, the sample size would have to be increased to 411 patients (Freedman, 1982) . It is important to note that these sample-size estimates were derived from standard tables, which are predicted entirely on survival differences at a specific endpoint. Thus these tables offer no insight into the relative impact of two important parameters -cured fraction and median survival time. Furthermore, there is no specific allowance for interaction of these parameters with clinical covariates, such as age of the patient. To overcome such limitations, we have devised an algorithm that simulates the dynamics of patients treated with adjuvant therapy more closely than is possible with standard tables.
Using this algorithm, we will address the power of a clinical trial for stage 2 breast carcinoma from a different perspective: Given a treatment that achieves biologically meaningful improvements in cure rate, median survival time, or both, how does our ability to detect a statistically significant survival difference vary as a function of number of patients enrolled and duration of the study?
Materials and methods

The lognormal survival model
Early and important insight into mortality from cancer was gained with the classic publication of Boag in 1949. In this landmark article, he distinguished the role of cured fraction from that of time to death among uncured patients. He also showed that the distribution of time to death from many cancers was closely approximated by a lognormal function.
Expanding upon this initial work, Rutqvist studied 14,731 patients with breast carcinoma, including a sub-population of 5.252 patients with stage 2 disease (Rutqvist et al., 1984) . He confirmed the lognormal function as a good fit to the distribution of time to death from breast carcinoma, and characterised the distribution of age among patients with each stage of breast cancer. Furthermore, he found that cured fraction varies substantially as a function of both patient age and tumour stage, while median survival time varies substantially with tumour stage but only minimally with patient age. For stage 2 patients, the overall cured fraction was 0.27 and the median survival time was 3.4 years.
The population algorithm This algorithm was designed to generate data sets for survival analysis of patients with stage 2 breast carcinoma. In these sets, survival-related covariates followed essentially the same distributions found by Rutqvist in his sub population of 5252 patients. To achieve such distributions, patients were randomly assigned ages that followed a Gaussian distribution, with a mean of 55.2 years and a standard deviation of 12.9 years, omitting values less than 10 years or greater than 90 years. The following regressions were used to achieve a relationship of age to cured fraction and mean and standard deviation of log survival time similar to that found by Rutq- To determine whether a patient was dead of tumour; a random number uniformly distributed between 0 and 1 was selected. If this number was greater than C', the patient was considered dead of tumour at a time randomly selected from a lognormal distribution with mean M' and standard deviation S. Uniformly distributed random numbers were generated by the HP9836 BASIC algorithm, while those from a Gaussian distribution were generated by the Box-Muller algorithm (Hewlett-Packard, 1985; Morgan, 1984) .
Note that for T = 0 or for Ac = AM = 0, there is no change in cured fraction (i.e., C' = C) or median survival time (i.e., exp{M'} = exp{M}), while for T = Ac = AM = 1, both parameters are increased by a factor of 2 for treated patients (i.e., T = 1, C' = 2 C, exp{M'} = 2 exp{M}). For Ac = AM = 0.5, both parameters are enhanced by 50 percent for treated over untreated patients.
Allowance was also made for death from causes other than breast carcinoma. Each patient was randomly assigned an integer between 1 and 9. An examination was then made of standardised survival data for the general population of females in the United States for 1980. If, for example, a hypothetical patient was assigned an age of 55 years and an integer of 7, then this patient was assigned a time to death from other causes equal to the seventh decile of time to death among the general female population for that age (i.e., that time by which 70% of 55 year old women would be dead of any cause).
Duration of followup for each patient was selected as a random number uniformly distributed between the limits of the study. For example, in a 5 year study with three years of additional followup, duration of followup for each patient would be a randomly selected line between three and eight years, rounded to a maximum of two decimal places.
For this study, both Ac andAM were allowed to vary between 0 and 1.0 in increments of 0.1, yielding a total of 33 possible combinations -i.e., Ac = 0 to 1.0 while AM = 0, AM = 0 to 1.0 while Ac = 0, and Ac = AM = 0 to 1.0. For each combination, a total of 1000 'clinical trials' were 'conducted'. Each set of 33,000 trials was performed with the following parameters:
Set 1: Total patients = 500, additional followup = 3 years Set 2: Total patients = 500, additional followup = 5 years Set 3: Total patients = 750, additional followup = 3 years. For all trials, recruitment occured over 5 years, so that maximum followup was either 8 years (3 years of additional followup) of 10 years (5 years of additional followup).
For each trial, log-rank analysis was performed in the standard fashion (Peto et al., 1977) , ending each interval of analysis at the time when one or more deaths occurred.
Results
Results are shown in Table I . It can be seen that an increase in additional followup from 3 to 5 years enhances the ability of the log-rank test to detect a survival difference produced by an improvement in cured fraction, but diminishes slightly the ability of this method to detect a survival difference produced by enhancement in median survival time. The explanation for this seemingly paradoxical effect can be discovered from an examination of Figures la and lb; with improved cured fraction alone, there is a progressive increase in the survival difference between treated and control patients, while with enhanced median survival time alone, this difference declines after approximately 8 years. 
Discussion
The fundamental goal of cancer therapy is to cure patients of their entire tumour burden, so that the treated cancers pose no further threat to life. Unfortunately, given the practical constraints of therapeutic trials, we must rely on a secondary measure of success -improved survival within 5 to 10 years of initial treatment. Such an improvement, as can be seen in Figure 1 , does not assure an increase in cure rate, but rather may reflect only an increase in survival time.
Although increased survival time is a worthy goal, its value to the patient must be weighed against the personal and social costs of adjuvant therapy. Women may be less willing to spend months suffering the side-effects of cytotoxic drugs when the potential payoff is months of extra life, rather than a substantial increase in the likelihood of cure. This dichotomy is especially compelling among young women, for whom a cure can mean decades of productive and diseasefree life.
Even though several clinical trials have documented the 'benefit' of adjuvant therapy, our analysis offers no reassurance that modem therapy is curing a substantial portion of women with stage 2 breast cancer. On the contrary, a proportional increase in median survival time led to a more consistently detected survival difference by log-rank analysis than an increase of equal proportion in cured fraction. Thus, given the time constraints of many clinical trials, these detectable differences may reflect only a prolongation of survival time.
It is important to note that this limitation is independent of the level of significance achieved with the log-rank testi.e., an especially small P-value does not assure that a treatment benefit results from enhancement of cured fraction. Furthermore, we cannot expect better results from other non-parametric methods of survival analysis (Peto et al., 1977) . As this article points out, the log-rank statistic is an excellent test of the null hypothesis (no significant difference in survival at specific endpoint), even if the hazards are not proportional in the two treatment groups, as they were not in our simulated populations. On the other hand, we can detect a specific therapeutic enhancement of cured fraction with certain parametric methods. Unfortunately, these methods often require large data sets and prolonged followup (Boag, 1949; Gamel et al., 1990; Mould & Boag, 1975) .
In closing, we must consider the limitations of this study. The findings described above are to some extent dependent on the model we selected. Perhaps the true parameters of patients with stage 2 breast carcinoma differ substantially from those parameters programmed into the hypothetical populations studied in this report. Because of such uncertainties, we would not propose basic changes in the design of clinical trials based on this evidence alone.
One conclusion, however, is clearly drawn, as can be seen in Figure 1 . With increasing followup, it becomes progressively more likely that a persistent difference in survival is due to enhanced cure rate rather than enhanced survival time alone. Given this fact, and given the social and financial cost of therapeutic trials, perhaps we should continue indefinitely our efforts to obtain followup data on these patients. Important efforts in this direction have been accomplished by the National Cancer Data Base (USA), which represents a nationwide collection of clinical data from selected cancers (Steele et al., 1992) and by the Cancer Registry of Norway. Furthermore, perhaps we should strive for the largest feasible sample size, even if this exceeds the estimates derived from standard tables, since this would also enhance our ability to detect a true change in the cure rate.
